Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Astegolimab or Efmarodocokin Alfa in Severe COVID-19 Pneumonia
NCT04386616Phase 2Completed
- Sponsor
- Genentech
- Start
- Jun 2020
- Primary completion
- Jan 2021
- Modality
- Monoclonal Antibodies, Fc-Fusion Proteins
- Countries
- 4
01
Overview
Phase 2, randomised, double-blind trial in COVID-19 pneumonia comparing Placebo + SOC, Astegolimab + SOC and Efmarodocokin alfa + SOC (3 arms). Primary endpoint: Time to Recovery (Clinical Status Score 1 or 2) at 28 days. Started Jun 2020; status: completed.
02
Drugs
astegolimabefmarodocokin alfa
03
Conditions
COVID-19 pneumonia
Beyond the preview
Go deeper on NCT04386616.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04386616.